Still sees 2025 year-end 2025 cash $280M-$320M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals Completes Key Study on Gastroparesis Treatment
- Vanda Pharmaceuticals (VNDA) Q2 Earnings Cheat Sheet
- Vanda Pharmaceuticals’ Study on Trichostatin A: A Potential Game-Changer in Hematologic Malignancies
- Vanda Pharmaceuticals doses first patient in trial of VCA-894A
- Vanda Approves Key Proposals at Annual Meeting